238 related articles for article (PubMed ID: 22748655)
21. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
[TBL] [Abstract][Full Text] [Related]
22. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6767-71. PubMed ID: 16203762
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas.
Rhee DJ; Kong DS; Kim WS; Park KB; Lee JI; Suh YL; Song SY; Kim ST; Lim DH; Park K; Kim JH; Nam DH
Clin Neurol Neurosurg; 2009 Nov; 111(9):748-51. PubMed ID: 19716649
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of disease: temozolomide and glioblastoma--look to the future.
Mrugala MM; Chamberlain MC
Nat Clin Pract Oncol; 2008 Aug; 5(8):476-86. PubMed ID: 18542116
[TBL] [Abstract][Full Text] [Related]
26. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Bracht LK; Wen P; Meyerhardt JA; Kulke MH; Hornick JL; Redston M; LaFrankie DC; Black PM; Kesari S; Norden A; Drappatz J
J Clin Oncol; 2008 Oct; 26(29):4843-4. PubMed ID: 18779600
[No Abstract] [Full Text] [Related]
27. Elderly patients with glioblastoma: the treatment challenge.
Fiorentino A; De Bonis P; Chiesa S; Balducci M; Fusco V
Expert Rev Neurother; 2013 Oct; 13(10):1099-105. PubMed ID: 24117272
[TBL] [Abstract][Full Text] [Related]
28. Similar Trials With Differing Outcomes: Reconciliation in Glioblastoma.
Chamberlain MC
J Clin Oncol; 2016 Jan; 34(3):291-2. PubMed ID: 26628477
[No Abstract] [Full Text] [Related]
29. Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review.
Liu Y; Hao S; Yu L; Gao Z
World J Surg Oncol; 2015 Apr; 13():142. PubMed ID: 25889578
[TBL] [Abstract][Full Text] [Related]
30. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Johannessen TC; Bjerkvig R
Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898
[TBL] [Abstract][Full Text] [Related]
31. Going past the data for temozolomide.
Villano JL; Letarte N; Bressler LR
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1113-5. PubMed ID: 22147076
[TBL] [Abstract][Full Text] [Related]
32. Status quo--standard-of-care medical and radiation therapy for glioblastoma.
Becker KP; Yu J
Cancer J; 2012; 18(1):12-9. PubMed ID: 22290252
[TBL] [Abstract][Full Text] [Related]
33. Prime time for molecular marker diagnostics in neuro-oncology.
Weller M; Stupp R
Curr Opin Neurol; 2012 Dec; 25(6):743-4. PubMed ID: 23041956
[No Abstract] [Full Text] [Related]
34. IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Yamaguchi S; Tanino M; Murata J; Houkin K
Brain Tumor Pathol; 2013 Apr; 30(2):67-72. PubMed ID: 22752663
[TBL] [Abstract][Full Text] [Related]
35. Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients.
Oh T; Rutkowski MJ; Safaee M; Sun MZ; Sayegh ET; Bloch O; Tihan T; Parsa AT
J Clin Neurosci; 2014 Dec; 21(12):2129-34. PubMed ID: 25037316
[TBL] [Abstract][Full Text] [Related]
36. Treating glioblastoma multiforme with electrical fields.
Peruzzi P; Chiocca EA
World Neurosurg; 2010; 74(2-3):208-11. PubMed ID: 21492532
[No Abstract] [Full Text] [Related]
37. Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment.
Groves MD; Plummer AB
Continuum (Minneap Minn); 2012 Apr; 18(2):421-5. PubMed ID: 22810137
[TBL] [Abstract][Full Text] [Related]
38. [Temozolomide in patients with a glioblastoma multiforme: new developments].
Bromberg JE; Postma TJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
[TBL] [Abstract][Full Text] [Related]
39. [Update on cerebral tumors].
Benouaich-Amiel A; Delattre JY
Bull Cancer; 2006 Jan; 93(1):73-81. PubMed ID: 16455509
[TBL] [Abstract][Full Text] [Related]
40. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
